Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Analysis of Revenues 

Microsoft Excel

Revenues as Reported

Edwards Lifesciences Corp., income statement, revenues

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Transcatheter Aortic Valve Replacement 3,422,500 2,857,300 2,737,900 2,283,800 2,023,800
Transcatheter Mitral and Tricuspid Therapies 86,000 41,800 28,200 2,900 3,400
Surgical Structural Heart 889,100 761,800 841,700 761,600 807,100
Critical Care 834,900 725,400 740,200 674,500 601,000
Net sales 5,232,500 4,386,300 4,348,000 3,722,800 3,435,300

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Item Description The company
Net sales Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Edwards Lifesciences Corp. net sales increased from 2019 to 2020 and from 2020 to 2021.